Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination (Q37574913)

21 August 2017

1 reference

title

Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination (English)

1 reference

21 August 2017

Andrew S Bomback

1

1 reference

21 August 2017

Robert Toto

series ordinal

2

1 reference

21 August 2017

publication date

6 August 2009

1 reference

Journal of Clinical Hypertension

21 August 2017

published in

1 reference

21 August 2017

volume

22

1 reference

21 August 2017

issue

10

1 reference

21 August 2017

page(s)

1032-1040

1 reference

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Lessons from the African-American Study of Kidney Disease and Hypertension: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Renal and retinal effects of enalapril and losartan in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Aldosterone in the development and progression of renal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Aliskiren: the first renin inhibitor for clinical treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Structure-based design of aliskiren, a novel orally effective renin inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Renin inhibition: what are the therapeutic opportunities?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Renin inhibition with aliskiren: where are we now, and where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Angiotensin II receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Supramaximal dose of candesartan in proteinuric renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Long-term, high-dosage candesartan suppresses inflammation and injury in chronic kidney disease: nonhemodynamic renal protection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Drug dosing for renoprotection: maybe it's time for a drug efficacy-safety score?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Incremental prognostic value of changes in B-type natriuretic peptide in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysi

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

The incidence and implications of aldosterone breakthrough

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Effectiveness of aldosterone blockade in patients with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

"Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Beneficial impact of spironolactone in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor bl

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Renal aspirin: will all patients with chronic kidney disease one day take spironolactone?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively rises

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Aliskiren combined with losartan in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

7 January 2021

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

7 January 2021

Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

7 January 2021

Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

7 January 2021

Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

7 January 2021

Reactive Hyperreninemia Is a Major Determinant of Plasma Angiotensin II During ACE Inhibition

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

7 January 2021

Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

7 January 2021

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

7 January 2021

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

7 January 2021

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

7 January 2021

Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

7 January 2021

Determinants of angiotensin II generation during converting enzyme inhibition

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

7 January 2021

Maximizing inhibition of the renin-angiotensin system with high doses of converting enzyme inhibitors or angiotensin receptor blockers

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

7 January 2021

Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

7 January 2021

Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

7 January 2021

Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

7 January 2021

Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

7 January 2021

Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotens

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

7 January 2021

Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

7 January 2021

Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

7 January 2021

Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

7 January 2021

Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2009.138

7 January 2021

Identifiers

DOI

10.1038/AJH.2009.138

1 reference

21 August 2017

1 reference